Serum anti-Mullerian hormone predicts ovarian response in 
(Macaca fascicularis) monkeys

Hui Long 2,†, Yanhong Nie 1,†, Li Wang 2,†, Yong Lu 1, Yan Wang 1, Yijun Cai 1, Zhen Liu 1, 
Miaomiao Jia 2, Qifeng Lyu 2,*, Yanping Kuang 2,*, Qiang Sun 1,*

1 Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate 
Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai 
Institutes for Biological Sciences, Chinese Academy of Sciences, 120 Yueyang Road, Shanghai 200031, 
China.

2 Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong 
University School of Medicine, 639 Zhizaoju Rd, Shanghai 200001, China.

† The authors consider that the first three authors should be regarded as joint first authors

* The co-correspondent authors: Qiang Sun: qsun@ion.ac.cn; Yanping Kuang: Kuangyanp@126.com; 
Qifeng Lyu: lyuqifeng@126.com

Key words: Anti-mullerian hormone; prediction; number of retrieved oocytes; ovarian response; 
cynomolgus monkeys
Abstract

AMH as a promising predictor of ovarian response has been studied extensively in women undergoing assisted reproductive technology treatment, but little is known about its prediction value in monkeys undergoing ovarian stimulation. In current study, a total of 380 cynomolgus monkeys ranging from 5 to 12 yr received 699 ovarian stimulation cycles. Serum samples were collected for AMH measure with enzyme-linked immunosorbent assay. It was found that serum AMH levels were positive correlated with the number of retrieved oocytes (p<0.01) in the first, second and third stimulation cycles. In the first cycles, area under the curve (ROC$_{AUC}$) of AMH is 0.688 for low response and 0.612 for high response respectively, indicating the significant prediction values (p=0.000 and p=0.005). The optimal AMH cut-off value was 9.68 ng/ml for low ovarian response, and 15.88 ng/ml for high ovarian response prediction. In the second stimulation cycles, the significance of ROC$_{AUC}$ of AMH for high response rather than the low response was observed (p=0.001 and p=0.468). The optimal AMH cut-off value for high ovarian response was 15.61 ng/ml. In the third stimulation cycles, AMH lost the prediction value with no significant ROC$_{AUC}$. Our data demonstrated that AMH, not age, is a cycle dependent predictor for ovarian response in form of oocyte yields, which would promote the application of AMH in assisted reproductive treatment (ART) of female cynomolgus monkeys. AMH evaluation would optimize candidate selection for ART and individualize the ovarian stimulation strategies, and consequentially improve the efficiency in monkeys.
**Introduction**

Due to the similarities to human beings in reproductive physiology and endocrinology, nonhuman primates have been served as an ideal model for human reproductive biology, gynecology and other diseases (1-3), especially the cynomolgus monkeys with no seasonal breeding. To date, assisted reproductive technology (ART) were routinely applied in non-human primates to produce in vitro-derived embryos and offspring, which largely advanced the research of somatic cell nuclear transfer and the embryo stem cell establishment (4, 5). These achievements dependent on an amount of oocytes retrieval in ovarian stimulation. However, ovarian stimulation regimen in nonhuman primates has not been set up as well as human beings, and the high cost of medicine used also limited the availability of large number of oocytes. Regarding to ovarian stimulation, the efficiency of ART in nonhuman primates has the great potential to improve.

In controlled ovarian stimulations, the characteristics, such as age, menstrual cycle length, and results from previous in vitro fertilization (IVF) cycles are generally considered for ovarian stimulation strategies. Apart from these factors, several ovarian markers, such as antral follicle count (AFC) (6), estradiol concentration (7), basal FSH (8), inhibin and AMH (9), have been used to estimate the ovarian response to tailor ovarian stimulation protocols in human beings (10). As for the advancement in clinic practices to obtain satisfactory results, it is valuable to evaluate ovarian response to gonadotropin before ART in monkeys.

AMH is a homodimeric glycoprotein and secreted from preantral and small antral
follicles as recruited from the follicle pool in females (11,12). Thus it is considered as the reliable marker of ovarian reserve, reflecting both the quantity and the quality of the resting primordial ovarian follicle pool (13). Both woman and female monkeys have the similar AMH expression pattern, with a peak during the fertility period and becoming undetectable around the menopause (14,15,16). Further, AMH exhibited lower inter- and intra-cycle variability (17, 18), which make it a better predictor of ovarian response in IVF cycles than both AFC and FSH level (10). To date, AMH is widely used in prediction of ovarian response and clinical outcomes in humans (19) and other species, such as cow (20), sheep (21) and goats (22). However, the role of AMH in prediction of ovarian response in monkeys has not been uncovered.

Considering the great importance of nonhuman primate models and promising applications of AMH in ART, its predictability in monkeys deserved to be assessed. The present study was aim to explore the correlation between serum AMH levels and the number of retrieved oocytes after ovarian stimulation and determine the role of AMH as a predictor for the ovarian response in monkeys undergoing IVF cycles, which will help to individualize and optimize the ovarian stimulation regimen in nonhuman primates.

Materials and methods

Animals

A total of 380 cynomolgus monkeys and 699 cycles were included. Animals were maintained in social groups and housed in outdoor compounds with attached indoor
quarters. The use and care of animals complied with the guideline of the Biomedical Research Ethics Committee at the Shanghai Institutes for Biological Science (CAS) under the approval application entitled “Reproductive physiology of cynomolgus monkeys and establishment transgenic monkeys” (#ER-SIBS-221106P). They had menstrual of cycles between 22 and 36 days and had no hormone exposure during the last 2 months before testing AMH levels. Our data showed that ovarian stimulation had no effect on AMH levels. No significant differences were observed in serum AMH levels among the groups receiving different times of ovarian stimulation cycles at given age (supplementary figure 1, P>0.5).

**Ovarian stimulation treatment and oocyte retrieval**

Ovarian stimulation was conducted as the routine protocol. The initial dose of 15-30 IU FSH (Recombinant Human Follitropin for Injection; Merck Serono SA Aubonne Branch. Co.) was administrated twice a day from menstrual cycle day 3. Ovarian sizes of monkeys were monitored by B-scan ultrasonography from menstrual cycle day 10 onward. 1000-1500 IU HCG (Chorionic gonadotropin human; SIGMA-ALDRICH, Co.) were used to trigger ovulation when more than 10 follicles were larger than 3mm in diameter. 33-38 hours after hCG administration, monkeys were anesthetized with tiletamine hydrochloride (4 to 6 mg/kg, Zoletil 50; Virbac S.A.) intramuscularly, and cumulus-oocyte complexes (COCs) were collected by laparoscopic follicular aspiration.

**AMH assay**
Blood was withdrawn via an intravenous catheter and transferred into tubes for centrifugation. All serum was isolated from blood samples and was measured using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions (AMH ELISA, AL-105, Ansh Labs, USA) (15, 16). The assay was validated by demonstrating parallelism between the standard curve and the serially diluted monkey serum samples. High and low AMH calibrators were run in all assays and the values were within the assay’s acceptable ranges. The range of the AMH standards used in the assay was from 0.09 to 16.4 ng/ml. The intra-assay coefficients of variation were less than 8%, and inter-assay coefficient less than 12%.

**Statistical analysis**

One way ANOWA and t tests were used to compare the differences in three and two groups respectively. Pearson correlation coefficients were performed to examine the associations among serum AMH, age and oocyte outcome in different stimulation cycles. ROC curve was used to analysis the sensitivity and specificity of AMH at different levels in predicting low ovarian response (number of retrieved oocytes ≤14) and high ovarian response (number of retrieved oocytes ≥51) respectively (about 10% of the cohort was defined as the low or high responders in our study). High and normal response data were used for cut-off values analysis for high response, and low and normal response data were used for cut-off values analysis for low response. Significance was assigned at P<0.05. All analyses were performed using SPSS software package (24.0) or SigmaPlot (10.0).
Results

Characteristics and oocyte retrieval

A total of 380 female cynomolgus monkeys were included in this study. The statistical characteristics of age, AMH and oocytes retrieved from 699 ovarian stimulation cycles were categorized according to the number of cycle times and summarized in Table 1. Both age and serum AMH levels were similar among the three different stimulation cycles \((p=0.089, \ p=0.706, \text{ respectively, Table 1})\). There was no significance in the number of retrieved and metaphase II (MII) oocytes between the first and second stimulation cycles, and also between the second and third cycles (Table 1). Compared with the first cycles, the significant decline in the number of retrieved oocytes rather than metaphase II was observed in the third cycles \((33.6 \pm 20.5 \ vs \ 27.6 \pm 18.9, \ p<0.01, \text{ Table 1})\).

Correlations of age, AMH, and oocyte outcomes

To determine the effect of ovarian stimulation on AMH level, samples from the monkeys who received repeated ovarian stimulation were analyzed. There was no difference observed in AMH levels among different age groups from 5 to 12 yr. In the same age section, no significant differences were observed in AMH levels among the groups undergoing different times of ovarian stimulation (supplement Figure 1), indicating that AMH were relative stable across several stimulation cycles. Then, pearson correlation analysis was conducted to examine the relationships of AMH and age in the total participants. Our data revealed that AMH levels were positively
correlated with age ($r=0.151$, $p=0.002$, Table 2).

Univariate analysis showed that both the number of retrieved oocytes and MII oocytes had no relationships with age ($p>0.05$, Table 2) in all stimulation cycles, but showed a positive correlation with AMH level in the first and second stimulation cycles ($p<0.05$, Table 2). In the third cycles, although there also was a positive correlation between AMH levels and the number of retrieved oocytes ($r=0.316$, $p=0.009$), the number of MII oocytes showed no significant correlation with AMH ($r=0.211$, $p=0.083$, Table 2).

**AMH for prediction of low and high ovarian response**

Receiver operator curves (ROC) were plotted to depict the predictive potential of AMH in low and high ovarian response in stimulation cycles. The area under the curve of ROC ($\text{ROC}_{\text{AUC}}$) exhibited the ability of AMH levels for predicting the high and low response in the first cycles, and the high response in the second cycles ($p<0.05$), while no significant $\text{ROC}_{\text{AUC}}$ was observed in the third cycles (Table 3). The sensitivity and specificity of AMH at different levels were analyzed in predicting value. The cutoff values were determined as well.

**AMH cutoff values in the first stimulation cycles**

The ROC curves of AMH concentrations predicting female monkeys with low and high ovarian response in the first cycles compared with normal ovarian response are showed in Figure 1 and Table 3. $\text{ROC}_{\text{AUC}}$ of AMH is 0.688 for low response (95% CL: 0.604 to 0.771) and 0.612 for high response (95% CL: 0.541 to 0.683) respectively, indicating a useful potential for prediction ($p=0.000$ and $p=0.005$, Table 3). The
optimal AMH cut-off value predicting low and normal ovarian was 9.68 ng/ml (sensitivity: 45.5%, specificity: 87.8%), and high and normal ovarian was 15.88 ng/ml (sensitivity: 66.7%, specificity: 52.9%).

**AMH cutoff values in the second stimulation cycles**

The ROC curves of AMH concentrations predicting female monkeys with low and high ovarian response in the second cycles compared with normal ovarian response are showed in Figure 1 and Table 3. The ROC_{AUC} of AMH is 0.535 for low response (95% CL: 0.435 to 0.636) and 0.673 for high response (95% CL: 0.584 to 0.784) respectively. The significance of ROC_{AUC} of AMH for high response rather than the low response was observed in the second cycles (p=0.001, and p=0.468, respectively, Table 3), indicating the potential predictive utility. The optimal AMH cut-off value for high ovarian response was 15.61 ng/ml (sensitivity: 82.4%, specificity: 54.3%) compared with the normal response.

**Discussion**

This study represents the first published report of AMH prediction of ovarian response in monkeys undergoing ovarian hyperstimulation. Our data demonstrated a positive association between serum AMH and the number of retrieved oocytes in 699 stimulation cycles of cynomolgus monkeys ranged from 5 to 12 yr ($p<0.01$). Allowing for chronologic age, AMH can be regarded as a significant predictor of poor and high ovarian response in the first stimulation cycles and high ovarian response in the second cycles ($p<0.001$), but lost the prediction role of low ovarian response in the
second and both responses in the third stimulation cycles from ROC analysis. It is possible due to the decrease in the number of retrieved oocytes after repeated cycles, but AMH still maintained stable between the cycles shown in our data.

Regarding to the ovarian response in repeated cycles, there are disagreements in the results reported. Some studies showed that the ovarian responses were similar in consecutive cycles (23), while others reported that ovarian stimulations led to the decrease of the retrieved oocytes in rhesus monkey (24). Our data showed that, there was a decline in the number of retrieved oocytes with the growing stimulation accounts, which consequently led to the different predictability of AMH in the first, second and third stimulation cycles. The decrease of oocyte yields was also observed in rhesus monkeys undergoing repeated ovarian stimulation (24). It is proved that repeat ovarian stimulations only altered the expression of proteins in ovaries, but not ovarian structure and function (25), which might be the reason why AMH level maintained stable indicated in our data.

Age is one of the traditional factors used for measuring the ovarian reservation in humans (10, 26). With age, ovarian reservation falls to a critical level, finally leading to menopause. As well, nonhuman primates have the similar characteristics (15). In the cohort of cynomolgus monkeys during the primary fertility period, age showed the positive correlation with AMH levels, but had no significant correlation with the number of retrieved oocytes observed in our data. Even though age can partially reflect ovarian aging related to the decline of the quantity and quality of the follicle pool, it is not an appropriate predictor in ovarian response in monkeys that was also
proved in humans (10). In addition, the comparison of predictive value between AMH and other ovarian markers, such as AFC and FSH, has not performed in current study for lacking of strict hormone monitor as in humans during ovarian stimulation, which limited the acknowledge of other ovarian response predictors in monkeys.

Using cutoffs of AMH to select appropriate candidates for ovarian stimulation will improve the efficiency of ART in monkeys. Definitely, the cutoff values with high sensitive and specificity can only be considered as screening marker. In the first stimulation cycles, the AMH cutoff value was 9.68 ng/ml for predicting low ovarian response with a specificity of 87.8% and a sensitivity of 45.5%. It is clear that AMH had a modest sensitivity for poor response, and thus it would include the candidates with poor response for ovarian stimulation. The higher cutoff values than 9.68 ng/ml should be considered for exclusion of false negative ones in practice. On the other hand, the individual adjustment of the dose of gonadotropins in poor responders is also effective to increasing the success rate of ovarian stimulation. In regard to high response, the cutoff values of AMH were similar in the first and second stimulation cycles, while had different sensitivity and specificity. Considering the potential risk of ovarian hyper stimulation syndrome (OHSS) in primates, the high sensitivity was preferable.

It is well known that AMH levels, as a marker of severity of ovarian dysfunction, are elevated up to two- to threefold in PCOS patients (27). PCOS is most common cause of infertility, and the occurrence reached 6-10% in women of reproductive age (28). The PCOS like status are believed existing in an unselected cohort of
cynomolgus monkeys during fertility period. Thus, high AMH level, especially much higher than the cutoff value for high ovarian response should be ill advised for ovarian stimulation, due to the potential bad quality of retrieved oocytes and risk of OHSS.

Taken together, serum AMH can be used as a cycle dependent predictor of ovarian response in cynomolgus monkeys treated with ovarian stimulations. It will provide the reference criteria for candidate selection for ART in monkeys. The optimal AMH cutoff values gained in this study will promote the individualization and optimization of ovarian stimulation regimen and therefore improve the efficiency of ART in cynomolgus monkeys.

Declaration of interest

None conflict of interest declared.

Funding

This work was supported by grants from Shanghai Municipal Government Bureau of science and technology project (16JC1420202 to Q.S), Natural Science Foundation of China (81571397, 81771533 to Y. K. 81571486 to Q.L.

Author contributions

Hui Long, Yanhong Nie, Li Wang and Miaomiao Jia participated in experiment execution and manuscript drafting; Yong Lu and Yan Wang participated in experiment execution and data analysis; Yijun Cai and Zhen Liu participated in data analysis and critical discussion; Qifeng Lyu, Yanping Kuang and Qiang Sun participated in study
design and critical discussion.

References

1 Terasawa E: Control of luteinizing hormone-releasing hormone pulse generation in nonhuman primates. Cell Mol Neurobiol 1995 15 141-164.

2 Appt SE: Usefulness of the monkey model to investigate the role soy in postmenopausal women's health. ILAR J 2004 45 200-211.

3 Freeman EW, Sammel MD, Lin H, Boorman DW, Gracia CR: Contribution of the rate of change of antimullerian hormone in estimating time to menopause for late reproductive-age women. Fertil Steril 2012 98 1254-1259 e1251-1252.

4 Byrne JA, Pedersen DA, Clepper LL, Nelson M, Sanger WG, Gokhale S, Wolf DP, Mitalipov SM: Producing primate embryonic stem cells by somatic cell nuclear transfer. Nature 2007 450 497-502.

5 Liu Z, Cai Y, Wang Y, Nie Y, Zhang C, Xu Y, Zhang X, Lu Y, Wang Z, Poo M et al: Cloning of Macaque Monkeys by Somatic Cell Nuclear Transfer. Cell 2018 172 881-887 e887.

6 Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ: AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011 17 46-54.

7 Hendriks DJ, Klinkert ER, Bancsi LF, Looman CW, Habbema JD, te Velde ER, Broekmans FJ: Use of stimulated serum estradiol measurements for the prediction of hyperresponse to ovarian stimulation in in vitro fertilization (IVF). J Assist Reprod Genet 2004 21 65-72.
8 Fourati S, Merdassi G, Khrouf M, Elloumi H, Fadhlaoui A, Brahmi I, Hammami N, Ben Slima S, Ben Meftah M, Zhioua F et al: [Basal fsh level is only predictive of the quantitative aspect of the ovarian response]. *Tunis Med* 2012 **90** 524-529.

9 Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC, Laven JS, Goverde AJ, Broekmans FJ, Themmen AP et al: Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. *J Clin Endocrinol Metab* 2009 **94** 786-792.

10 Jamil Z, Fatima SS, Ahmed K, Malik R: Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. *Dis Markers* 2016 **2016** 5246217.

11 Jeppesen JV, Anderson RA, Kelsey TW, Christiansen SL, Kristensen SG, Jayaprakasan K, Raine-Fenning N, Campbell BK, Yding Andersen C: Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. *Mol Hum Reprod* 2013 **19** 519-527.

12 McGee EA, Hsueh AJ: Initial and cyclic recruitment of ovarian follicles. *Endocr Rev* 2000 **21** 200-214.

13 Domingues TS, Rocha AM, Serafini PC: Tests for ovarian reserve: reliability and utility. *Curr Opin Obstet Gynecol* 2010 **22** 271-276.

14 Lie Fong S, Visser JA, Welt CK, de Rijke YB, Eijkemans MJ, Broekmans FJ, Roes EM, Peters WH, Hokken-Koelega AC, Fauser BC et al: Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. *J Clin Endocrinol Metab* 2012 **97** 4650-4655.
15 Atkins HM, Willson CJ, Silverstein M, Jorgensen M, Floyd E, Kaplan JR, Appt SE: Characterization of ovarian aging and reproductive senescence in vervet monkeys (Chlorocebus aethiops sabaeus). *Comp Med* 2014 *64* 55-62.

16 Appt SE, Clarkson TB, Chen H, Adams MR, Christian PJ, Hoyer PB, Wilson ME, Kaplan JR: Serum antimullerian hormone predicts ovarian reserve in a monkey model. *Menopause* 2009 *16* 597-601.

17 Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ: Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. *J Clin Endocrinol Metab* 2006 *91* 4057-4063.

18 La Marca A, Stabile G, Artenisio AC, Volpe A: Serum anti-Mullerian hormone throughout the human menstrual cycle. *Hum Reprod* 2006 *21* 3103-3107.

19 Broer SL, Broekmans FJ, Laven JS, Fauser BC: Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. *Hum Reprod Update* 2014 *20* 688-701.

20 Souza AH, Carvalho PD, Rozner AE, Vieira LM, Hackbart KS, Bender RW, Dresch AR, Verstegen JP, Shaver RD, Wiltbank MC: Relationship between circulating anti-Mullerian hormone (AMH) and superovulatory response of high-producing dairy cows. *J Dairy Sci* 2015 *98* 169-178.

21 Lahoz B, Alabart JL, Cocero MJ, Monniaux D, Echegoyen E, Sanchez P, Folch J: Anti-Mullerian hormone concentration in sheep and its dependence of age and independence of BMP15 genotype: an endocrine predictor to select the best donors for embryo biotechnologies. *Theriogenology* 2014 *81* 347-357.
22 Monniaux D, Baril G, Laine AL, Jarrier P, Poulin N, Cognie J, Fabre S: Anti-Mullerian hormone as a predictive endocrine marker for embryo production in the goat. *Reproduction* 2011 **142** 845-854.

23 VandeVoort CA, Tarantal AF: Recombinant human gonadotropins for macaque superovulation: repeated stimulations and post-treatment pregnancies. *J Med Primatol* 2001 **30** 304-307.

24 Yang S, Shen Y, Niu Y, Hildebrandt TB, Jewgenow K, Goeritz F, He X, Zhou Q, Ji W: Effects of rhFSH regimen and time interval on ovarian responses to repeated stimulation cycles in rhesus monkeys during a physiologic breeding season. *Theriogenology* 2008 **70** 108-114.

25 Dong G, Guo Y, Cao H, Zhou T, Zhou Z, Sha J, Guo X, Zhu H: Long-term effects of repeated superovulation on ovarian structure and function in rhesus monkeys. *Fertil Steril* 2014 **102** 1452-1457 e1451.

26 Vidal JD: The Impact of Age on the Female Reproductive System. *Toxicol Pathol* 2017 **45** 206-215.

27 Bungum L, Franssohn F, Bungum M, Humaidan P, Giwercman A: The circadian variation in Anti-Mullerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women. *PLoS One* 2013 **8** e68223.

28 Teede HJ, Norman R: Polycystic ovarian syndrome: insights into the enigma that is PCOS today. *Endocrine* 2006 **30** 1-2.

**Figure legends**

**Fig 1** AMH receiver operator characteristic (ROC) curves for low and high ovarian
response predictions in the first and second cycle respectively.
Fig 1 AMH receiver operator characteristic (ROC) curves for low and high ovarian response predictions in the first and second cycle respectively.

94x90mm (300 x 300 DPI)
Table 1 Characteristics of age, AMH and oocyte retrieval in different cycles.

|                      | First cycle (n=380) | Second cycle (n=251) | Third cycle (n=68) | p- value |
|----------------------|---------------------|----------------------|--------------------|----------|
| Age (years)          | 8.2±2.5             | 8.4±2.4              | 8.9±2.6            | 0.089    |
| AMH (ng/ml)          | 15.3±5.0            | 15.5±4.8             | 15.8±4.4           | 0.706    |
| Retrieved oocytes    | 33.6±20.5           | 31.3±12.3            | 27.6±18.9          | 0.048*   |
| MII oocytes          | 13.2±10.9           | 12.3±10.6            | 10.4±10.0          | 0.112    |

AMH, anti-mullerian hormone; MII, metaphase II. Values are presented as mean±SD. P-value by One way ANOVA. *, p<0.05. Compared with the second cycle, ##, p<0.001.
Table 2  Correlation analyses among age, AMH, the number of retrieved oocytes, and metaphase II oocytes in different ovarian stimulation cycles.

|                      | Age (years) |                      | AMH (ng/ml) |                      |
|----------------------|-------------|----------------------|-------------|----------------------|
|                      | Pearson     | p-value              | Pearson     | p-value              |
|                      | correlation |                      | correlation |                      |
|                      | coefficient |                      | coefficient |                      |
| Age (5-10 years)     |             |                      | r=0.151     | P=0.002**            |
| First cycle (n=380)  |             |                      | r=0.344     | p=0.000**            |
| No. of retrieved     | r=0.028     | p=0.583              | r=0.262     | p=0.000**            |
| oocytes              |             |                      |             |                      |
| No. of MII oocytes   | r=0.062     | p=0.231              | r=0.259     | p=0.000**            |
| Second cycle (n=251) |             |                      |             |                      |
| No. of retrieved     | r=0.034     | p=0.594              | r=0.179     | p=0.004**            |
| oocytes              |             |                      |             |                      |
| No. of MII oocytes   | r=0.020     | p=0.753              | r=0.316     | p=0.009**            |
| Third cycle (n=68)   |             |                      |             |                      |
| No. of retrieved     | r=0.219     | p=0.072              | r=0.211     | p=0.083              |
| oocytes              |             |                      |             |                      |
| No. of MII oocytes   | r=0.160     | p=0.192              |             |                      |

AMH, anti-mullerian hormone; MII, metaphase II. *Pearson* correlation analysis was performed. **, p<0.01.
Table 3 Potential of AMH to predict low and high response in different ovarian stimulation cycles.

| Cycle  | ROC<sub>AUC</sub> | 95% CI      | p-value | ROC<sub>AUC</sub> | 95% CI      | p-value |
|--------|-------------------|-------------|---------|-------------------|-------------|---------|
| First  | 0.688             | (0.604, 0.771) | 0.000*** | 0.612             | (0.541, 0.683) | 0.005** |
| Second | 0.535             | (0.435, 0.636) | 0.468   | 0.673             | (0.584, 0.761) | 0.001** |
| Third  | 0.642             | (0.499, 0.784) | 0.077   | 0.618             | (0.418, 0.818) | 0.102   |

AMH, anti-mullerian hormone; CI, confidence interval. P-value means significance of ROC<sub>AUC</sub> compared with 0.5. **, p<0.01. ***, p<0.001.